76 related articles for article (PubMed ID: 14663635)
1. Weekly docetaxel for patients with platinum/paclitaxel/irinotecan-resistant relapsed ovarian cancer: a phase I study.
Terauchi F; Hirano T; Taoka H; Masaki K; Yamamoto Y; Ogura H; Kubo H
Int J Clin Oncol; 2003 Dec; 8(6):348-51. PubMed ID: 14663635
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of weekly CPT-11 (irinotecan)/docetaxel in patients with advanced solid tumors.
Font A; Sanchez JM; Rosell R; Taron M; Martinez E; Guillot M; Manzano JL; Margeli M; Barnadas A; Abad A
Lung Cancer; 2002 Aug; 37(2):213-8. PubMed ID: 12140145
[TBL] [Abstract][Full Text] [Related]
3. Docetaxel in combination with irinotecan (CPT-11) in platinum-resistant paclitaxel-pretreated ovarian cancer.
Polyzos A; Kosmas C; Toufexi H; Malamos N; Lagadas A; Kosmidis C; Ginopoulos P; Ziras N; Kandilis K; Georgoulias V
Anticancer Res; 2005; 25(5):3559-64. PubMed ID: 16101180
[TBL] [Abstract][Full Text] [Related]
4. Phase I dose escalation trial of weekly docetaxel plus irinotecan in patients with advanced cancer.
Bleickardt E; Argiris A; Rich R; Blum K; McKeon A; Tara H; Zelterman D; Burtness B; Davies MJ; Murren JR
Cancer Biol Ther; 2002; 1(6):646-51. PubMed ID: 12642688
[TBL] [Abstract][Full Text] [Related]
5. Biweekly administration of 24-h infusion of irinotecan followed by a 1-h infusion of docetaxel: a phase I study.
Briasoulis E; Pentheroudakis G; Timotheadou H; Rammou D; Pavlidis N; Fountzilas G
Anticancer Drugs; 2004 Sep; 15(8):747-52. PubMed ID: 15494635
[TBL] [Abstract][Full Text] [Related]
6. Phase I and pharmacological study of single paclitaxel administered weekly for heavily pre-treated patients with epithelial ovarian cancer.
Takano M; Kikuchi Y; Kita T; Suzuki M; Ohwada M; Yamamoto T; Yamamoto K; Inoue H; Shimizu K
Anticancer Res; 2002; 22(3):1833-8. PubMed ID: 12168878
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer.
Johnson FM; Kurie JM; Peeples BO; Lee JJ; Feng L; Pisters KM; Fossella FV; Papadimitrakopoulou VA; Blumenschein GR; Komaki R; Glisson BS
Clin Lung Cancer; 2003 Jul; 5(1):40-5. PubMed ID: 14596703
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan.
Verschraegen CF; Kudelka AP; Hu W; Vincent M; Kavanagh JJ; Loyer E; Bastien L; Duggal A; De Jager R
Cancer Chemother Pharmacol; 2004 Jan; 53(1):1-7. PubMed ID: 14586557
[TBL] [Abstract][Full Text] [Related]
9. Phase I/II study of weekly docetaxel dose escalation in combination with fixed weekly cisplatin and concurrent thoracic radiotherapy in locally advanced non-small cell lung cancer.
Yamamoto N; Nishimura Y; Nakagawa K; Matsui K; Fukuoka M
Cancer Chemother Pharmacol; 2006 Sep; 58(3):285-91. PubMed ID: 16416334
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of weekly docetaxel for patients with relapsed ovarian cancer who have previously received paclitaxel--ANZGOG 02-01.
Tinker AV; Gebski V; Fitzharris B; Buck M; Stuart-Harris R; Beale P; Goldrick A; Rischin D
Gynecol Oncol; 2007 Mar; 104(3):647-53. PubMed ID: 17079006
[TBL] [Abstract][Full Text] [Related]
11. Weekly administration of topotecan and paclitaxel in pretreated advanced cancer patients: a phase I/II study.
Stathopoulos GP; Rigatos SK; Christodoulou C; Malamos NA; Deliyiannis F; Stathopoulos JG; Skarlos DV
Cancer Chemother Pharmacol; 2004 Sep; 54(3):259-64. PubMed ID: 15127231
[TBL] [Abstract][Full Text] [Related]
12. Combined irinotecan, docetaxel and conventionally fractionated radiotherapy in locally advanced head and neck cancer. A phase I dose escalation study.
Koukourakis MI; Bizakis JG; Skoulakis CE; Kyrmizakis D; Giatromanolaki A; Papadakis CE; Prokopakis E; Amanakis Z; Hellidonis ES
Anticancer Res; 1999; 19(3B):2305-9. PubMed ID: 10472349
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer.
Lordick F; von Schilling C; Bernhard H; Hennig M; Bredenkamp R; Peschel C
Br J Cancer; 2003 Aug; 89(4):630-3. PubMed ID: 12915869
[TBL] [Abstract][Full Text] [Related]
14. Phase I/II study of irinotecan, 5-fluorouracil, and l-leucovorin combination therapy (modified Saltz regimen) in patients with metastatic colorectal cancer.
Goto A; Yamada Y; Hosokawa A; Ura T; Arai T; Hamaguchi T; Muro K; Shimada Y; Shirao K
Int J Clin Oncol; 2004 Oct; 9(5):364-8. PubMed ID: 15549585
[TBL] [Abstract][Full Text] [Related]
15. Topotecan in platinum- and paclitaxel-resistant ovarian cancer.
Swisher EM; Mutch DG; Rader JS; Elbendary A; Herzog TJ
Gynecol Oncol; 1997 Sep; 66(3):480-6. PubMed ID: 9299264
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of docetaxel and irinotecan in patients with advanced non-small-cell lung cancer.
Nogami N; Harita S; Ueoka H; Yonei T; Kiura K; Kamei H; Tabata M; Segawa Y; Gemba K; Tanimoto M
Lung Cancer; 2004 Jul; 45(1):85-91. PubMed ID: 15196738
[TBL] [Abstract][Full Text] [Related]
17. Phase I clinical trial of weekly combined paclitaxel plus docetaxel in patients with solid tumors.
Lokich J
Cancer; 2000 Dec; 89(11):2309-14. PubMed ID: 11147602
[TBL] [Abstract][Full Text] [Related]
18. Salvage treatment with docetaxel for recurrent epithelial ovarian cancer.
Niwa Y; Nakanishi T; Kuzuya K; Nawa A; Mizutani S
Int J Clin Oncol; 2003 Dec; 8(6):343-7. PubMed ID: 14663634
[TBL] [Abstract][Full Text] [Related]
19. Docetaxel/irinotecan combination chemotherapy in platinum/taxane-refractory and -resistant ovarian cancer: JGOG/WJGOG Intergroup Study.
Ushijima K; Kamura T; Tamura K; Kuzuya K; Sugiyama T; Noda K; Ochiai K
Int J Clin Oncol; 2013 Feb; 18(1):126-31. PubMed ID: 22127346
[TBL] [Abstract][Full Text] [Related]
20. A phase I study and pharmacokinetics of irinotecan (CPT-11) and paclitaxel in patients with advanced non-small cell lung cancer.
Hotta K; Ueoka H; Kiura K; Tabata M; Kuyama S; Satoh K; Kozuki T; Hisamoto A; Hosokawa S; Fujiwara K; Tanimoto M
Lung Cancer; 2004 Jul; 45(1):77-84. PubMed ID: 15196737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
